Trial
NCT04221451
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Tay-Sachs Disease
Intervention
venglustat GZ402671
Why stopped
Discontinued based on the absence of positive trends on clinical endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-28